Tentative Outline

Special Thematic Issue for the journal: Current Drug Targets, ISSN NO: 1873-5592 (Online)
ISSN: 1389-4501 (Print)

Title of the Thematic Issue: Recent advances in the design and discovery of GSK-3 inhibitors for the treatment of diverse disease conditions

Guest Editors: Dr. Dilipkumar Pal, M Pharm, Ph D, FIC, Chartered Chemist, Post Doct (Australia)

- Scope:

Glycogen synthase kinase-3 (GSK-3), a constitutively active serine/threonine kinase, is a key regulator of numerous cellular processes ranging from glycogen metabolism to cell-cycle regulation and proliferation. Because of the diverse roles, malfunction of this kinase is also known to be involved in the pathogenesis of human diseases such as diabetes, inflammation, neurological disorders, and various neoplastic diseases. Therefore, GSK-3 is recognized as an attractive target for the development of new drugs.

- Keywords: GSK-3, T1-protein, Anti-inflammatory potential, Alzheimer's disease, brain cancer, Renal Cancer, breast and ovarian cancer, Gastrointestinal carcinoma.

Sub-topics:

The sub-topics to be covered within the issue should be provided:

- Recent advances in the discovery of GSK-3 inhibitors from synthetic origin in the treatment of neurological disorder:
- Anti-inflammatory potential of GSK-3 inhibitors
- GSK-3 antagonists in the treatment of Alzheimer's disease
- GSK-3 Inhibitors as new leads to treat type 2 diabetes mellitus
- Naturally occurring GSK-3 Inhibitor for the treatment of brain cancer
- Inhibition of GSK-3 Induces positive effects in Impaired Glucose Metabolism in Renal Cancer
- GSK-3 Inhibitors as new leads to treat breast and ovarian cancer
- Role of GSK-3 Inhibitors in control and regulation of Gastrointestinal carcinoma

Tentative titles of the articles and list of contributors:

Tentative titles of the articles and list of contributors with their names, designations, addresses and email addresses (Approx.).
1. Recent advances in the discovery of GSK-3 inhibitors from synthetic origin in the treatment of neurological disorder: Dr Supriyo Saha et al, Asst Professor, Department of Pharmaceutical Sciences, Sardar Bhagwan Singh PG Institute of Biomedical Sciences and Research, INDIA

2. Anti-inflammatory potential of GSK-3 inhibitors: Dr Sajal Medda et al, Professor in Pharmaceutical Chemistry, ADAMAS University, INDIA

3. GSK-3 antagonists in the treatment of Alzheimer's disease: Dr Dilipkumar Pal et al, Associate Professor, Department of Pharmaceutical Sciences, GURU GHASIDASH VISHWAVIDYALAYA (A Central University), Bilaspur, C.G., INDIA. E mail: drdilip71@gmail.com

4. GSK-3 Inhibitors as new leads to treat type 2 diabetes mellitus: Dr G Kiran et al, Associate Professor, Anurag Group of Institutions, INDIA

5. Naturally occurring GSK Inhibitor for the treatment of brain cancer: Dr S B Nimse et al, Asst Professor, Institute of Applied Chemistry, Hallym University, Chuncheon, South Korea.

6. Inhibition of GSK-3 Induces positive effects in Impaired Glucose Metabolism in Renal Cancer: Dr Amit Kumar Nayak, Associate Professor in Pharmacy, SIPS, Biju Pattanaik University of Technology, INDIA

7. GSK-3 Inhibitors as new leads to treat breast and ovarian cancer: Dr Phool Chandra et al, Associate Professor, School of Pharmaceutical Sciences, IFTM University, INDIA

8. Role of GSK-3 Inhibitors in control and regulation of Gastrointestinal carcinoma (not yet decided, from Foreign University)

Schedule:

Thematic issue submission deadline:
Submission To Publisher:
Abstract submission deadline: 30th November 2019
Full manuscript submission deadline: 31st August 2020

Contacts:

Guest Editor: Dr. Dilipkumar Pal
Affiliation: Associate Professor, Department of Pharmaceutical Sciences, Guru Ghasidas Vishwavidyalaya (A Central University), Bilaspur, C.G., 495 009, INDIA
Email: drdilip71@gmail.com